Close this search box.
Subscriber Log In

Next Generation Dealmaking with Evaluate and Inpart


Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need regular topping up to ensure companies can deliver long-term growth in the face of new competition, and loss of exclusivity. At Evaluate, we work closely […]

Quick View: Biopharma Dealmaking in Q3


The first half of the year showed some promise. Did the third quarter continue the trend? Well… If you read our round up of the state of the biopharma market at the halfway point of the year, you may have come away with, if not a spring in your step, then a least a little […]

BioSci Deal of the Month – Kite & Arcellx


In December of 2022, Kite and Arcellx entered an agreement to develop and commercialise Arcellx’s multiple myeloma product candidate CART-ddBCMA. The candidate is currently in Phase 2 clinical development and is a cell therapy product comprising of genetically modified autologous T cells. The collaboration brings together Arcellx’s promising CART-ddBCMA therapy with Kite’s expertise and leadership […]

BioSci Deal of the Month – Spero Therapeutics & GSK


In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr. Tebipenem HBr is an oral carbapenem antibiotic aimed at treating complicated urinary tract infections including pyelonephritis. GSK will receive an exclusive license to develop and commercialise Tebipenem pivoxil and tebipenem pivoxil HBr in all territories […]

BioSci Deal of the Month – Kainos Medicines & Emmaus Life Sciences


In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544). IRAK4 is a serine-threonine protein kinase known to be present and active in the occurrence of certain immunity responses, inflammation disorders, and various cancers. Under the terms of this agreement, Kainos will study […]